Western blot assay demonstrated that HADH expression was abundant in normal gastric tissue, weak in stage I-II GC, and barely detectable in stage III-IV GC tumors (Figure 1A), suggesting that HADH expression gradually decreases as GC progresses to a more advanced clinical stage. The gene discussed is HADH; the disease is gastric cancer.